TKI
Showing 1 - 25 of 1,196
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
Metabolic Alternation and Clinicohematological Characteristic in
Not yet recruiting
- CML, Chronic Phase
- Tyrosine kinase inhibitor
- (no location specified)
Nov 6, 2023
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
IASLC Grading System as a Predictor for EGFR-TKI Therapy
Completed
- Lung Cancer
- IASLC grading system
-
Shanghai, Please Select, ChinaChaoqiang Deng
Nov 9, 2023
Chronic Myeloid Leukemia Trial in Jena (Venetoclax)
Not yet recruiting
- Chronic Myeloid Leukemia
-
Jena, GermanyUniversitätsklinikum Jena
Jan 17, 2023
Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant
Completed
- The Primary Study Metric is Progression-free Survival (PFS)
- (no location specified)
Jun 28, 2023
Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)
Recruiting
- Liver Neoplasms
- Tislelizumab plus tyrosine kinase inhibitor
-
Beijing, Beijing, China302 Hospital
Sep 22, 2023
Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)
Recruiting
- Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
- Topical Timolol
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 14, 2023
NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)
Not yet recruiting
- Non-Small Cell Lung Cancer
- HS-10241+ Almonertinib
- Pemetrexed + Cisplatin /Carboplatin
- (no location specified)
Oct 29, 2023
NSCLC, EGFR Gene Mutation Trial in Nanjing (neo-antigen vaccine)
Recruiting
- NSCLC
- EGFR Gene Mutation
- neo-antigen vaccine
-
Nanjing, ChinaThe Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,
Oct 19, 2023
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy Trial (Trastuzumab Emtansine for Injection, Pyrotinib Maleate
Not yet recruiting
- HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
- Trastuzumab Emtansine for Injection
- Pyrotinib Maleate Tablets
- (no location specified)
Sep 30, 2022
NSCLC Trial in Singapore (Afatinib 40 MG)
Not yet recruiting
- NSCLC
- Afatinib 40 MG
-
Singapore, SingaporeNational University Hospital
Sep 25, 2023
Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)
Recruiting
- Gastrointestinal Stromal Tumors
- Apatinib Mesylate
- Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
-
Changsha, Hunan, ChinaXiangya Hospital, Central South University
Mar 1, 2023
EGFR Mutant Advanced NSCLC Trial (BBT-207)
Not yet recruiting
- EGFR Mutant Advanced Non-Small Cell Lung Cancer
- (no location specified)
Jun 16, 2023
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)
Not yet recruiting
- Tyrosine Kinase Inhibitors
- Chronic Myeloid Leukemia
- treatment of TKI in CML
-
Poitiers, FranceChu Poitiers
Feb 21, 2023
Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR
Not yet recruiting
- Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
- +6 more
- (no location specified)
Aug 9, 2022
Oligometastatic Disease, NSCLC, Driver Mutation Trial in Mumbai (Local Consolidative Radiation Therapy, TKI)
Recruiting
- Oligometastatic Disease
- +2 more
- Local Consolidative Radiation Therapy
- TKI
-
Mumbai, Maharashtra, IndiaTata Memorial Hospital
Mar 11, 2022
Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)
Recruiting
- Non-small-cell Lung Carcinoma
-
Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023
EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)
Not yet recruiting
- EGFR
- +2 more
- Almonertinib and metronomic oral vinorelbine
- (no location specified)
Dec 21, 2022
NSCLC Trial (Lazertinib group)
Not yet recruiting
- NSCLC
- Lazertinib group
- (no location specified)
Jul 14, 2022
NSCLC Trial in Chendu (Almonertinib)
Recruiting
- Non-small Cell Lung Cancer
-
Chendu, Sichuan, ChinaWest China Hospital,Sichuan University
Dec 14, 2022
Condition Vasoregulation Function Endothelium in CML Getting TKI
Recruiting
- Chronic Myeloid Leukaemia
- taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
-
Moscow, Russian Federation
- +1 more
Jan 11, 2023
Advanced NSCLC Trial (VIC-1911, Osimertinib Mesylate Tablets)
Not yet recruiting
- Advanced Non-small Cell Lung Cancer
- VIC-1911
- Osimertinib Mesylate Tablets
- (no location specified)
Aug 3, 2022
A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Oct 25, 2022